Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis Jun 4, 2026
Attralus Therapeutic AT-02 Receives Orphan Drug Designation from the U.S. FDA for the Treatment of ATTR Amyloidosis Nov 12, 2024
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA) May 30, 2024
Clinical Trial Design of AT-02 Phase 2 Open-Label Extension Study in Systemic Amyloidosis May 29, 2024
